Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 68 of 170 for:    cholangiocarcinoma | Recruiting, Not yet recruiting, Available Studies

Precise Treatment System of Biliary Malignancies Based on Special Disease Database

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03499782
Recruitment Status : Recruiting
First Posted : April 17, 2018
Last Update Posted : April 17, 2018
Sponsor:
Collaborators:
First Affiliated Hospital Xi'an Jiaotong University
The First Affiliated Hospital of Zhengzhou University
The First Affiliated Hospital of Dalian Medical University
Shanghai Zhongshan Hospital
Southwest Hospital, China
Tianjin Medical University Cancer Institute and Hospital
Sun Yat-sen University
Affiliated Hospital of North Sichuan Medical College
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Second Affiliated Hospital, School of Medicine, Zhejiang University
Eastern Hepatobiliary Surgery Hospital
Information provided by (Responsible Party):
Zhaohui Tang, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

Brief Summary:
Malignant tumors of biliary system lack standard treatment and precise prognosis assessment methods. This study including 12 hospitals, collecting clinical and follow-up data of patients with biliary malignant tumors including cholangiocarcinoma and gallbladder carcinoma in recent 10 years, aim to build a special disease database, then use Bayesian networks and importance theory to establish a mathematical model to assess treatment strategies and prognosis accurately. At the same time, data on biliary malignant tumors newly treated by multicenters from 2018 to 2020 will be included to validate, adjust and refine the models to guide clinical individualized precise treatment.

Condition or disease
Cholangiocarcinoma Gall Bladder Carcinoma Biliary System Disorder

Layout table for study information
Study Type : Observational
Estimated Enrollment : 10000 participants
Observational Model: Cohort
Time Perspective: Retrospective
Official Title: A Multi-center Study:Surgical Optimization and Prognosis Auxiliary System of Biliary Malignancies Based on Special Disease Database
Estimated Study Start Date : May 25, 2018
Estimated Primary Completion Date : August 31, 2021
Estimated Study Completion Date : December 31, 2021





Primary Outcome Measures :
  1. Death from biliary tract carcinoma [ Time Frame: Every three months, up to five years ]
    Death from cholangiocarcinoma or gallbladder carcinoma



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients Diagnosed with Gallbladder carcinoma or cholangiocarcinoma
Criteria

Inclusion Criteria:

  • Clinical diagnosis of biliary malignancy including gallbladder carcinoma or cholangiocarcinoma verified by pathological results
  • Must be able to undergo surgery
  • Undergoing radical surgery for biliary malignancy (R0 or R1 resection)
  • Not complicated with other malignancy
  • No other treatments before and during surgery, such as radiotherapy and chemotherapy.

Exclusion Criteria:

  • Non-primary gallbladder or cholangiocarcinoma
  • With distant metastasis (M1 phase)
  • Incomplete follow-up data
  • Died within 30 days after surgery.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03499782


Contacts
Layout table for location contacts
Contact: Zhaohui Tang, MD,PhD +86 13601789458 tangzhaohui@yahoo.com
Contact: Miaoyan Wei, MD,PhD +86 18516574578 doctor_vmy@163.com

Locations
Layout table for location information
China, Shanghai
Zhaohui Tang Recruiting
Shanghai, Shanghai, China, 200092
Contact: Miaoyan Wei    +86 18516574578    doctor_vmy@163.com   
Contact: Zhaohiu Tang Tang    +8613601789458    tangzhaohui@yahoo.com   
Sponsors and Collaborators
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
First Affiliated Hospital Xi'an Jiaotong University
The First Affiliated Hospital of Zhengzhou University
The First Affiliated Hospital of Dalian Medical University
Shanghai Zhongshan Hospital
Southwest Hospital, China
Tianjin Medical University Cancer Institute and Hospital
Sun Yat-sen University
Affiliated Hospital of North Sichuan Medical College
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Second Affiliated Hospital, School of Medicine, Zhejiang University
Eastern Hepatobiliary Surgery Hospital
Investigators
Layout table for investigator information
Study Director: Zhimin Geng, MD,PhD the first affiliated hospital of xi'an Jiaotong univerisity
Study Director: Peng Gong, MD,PhD the first affiliated hospital of Dalian medical univerisity
Study Director: Yu He, MD,PhD Southwest Hospital, China
Study Director: Shengping Li, MD,PhD Cancer Institute and Hospital Affiliated to Sun Yat-sen University
Study Director: Yinghe Qiu, MD,PhD Eastern Hepatobiliary Surgery Hospital
Study Director: Zhi Dai, MD,PhD Shanghai Zhongshan Hospital
Study Director: Tianqiang Song, MD,PhD Tianjin Medical University Cancer Institute and Hospital
Study Director: Yudong Qiu, MD,PhD The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Study Director: Jianying Lou, MD,PhD Second Affiliated Hospital, School of Medicine, Zhejiang University
Study Director: Jingdong Li, MD,PdD Affliated Hospital of North Sichuan Medical College
Study Director: Wenlong Zhai, MD,PhD The First Affiliated Hospital of Zhengzhou University

Layout table for additonal information
Responsible Party: Zhaohui Tang, Professor, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
ClinicalTrials.gov Identifier: NCT03499782     History of Changes
Other Study ID Numbers: XHEC-JDYXY-2018-002
First Posted: April 17, 2018    Key Record Dates
Last Update Posted: April 17, 2018
Last Verified: April 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Zhaohui Tang, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine:
Prognosis
Surgery options
Bayesian networks

Additional relevant MeSH terms:
Layout table for MeSH terms
Cholangiocarcinoma
Urinary Bladder Neoplasms
Adenocarcinoma
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Urologic Neoplasms
Urogenital Neoplasms
Neoplasms by Site
Urinary Bladder Diseases
Urologic Diseases